Showing results (91-100 of 114) with videos related to
Sort By:
Pageof 12
Blood Advances|November 4, 2020
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomaMarcelo C Pasquini, Zhen-Huan Hu, Kevin Curran, et al.The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.Journal of Hematology & Oncology|March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignanciesElvira Umyarova, Charles Pei, William Pellegrino, et al.The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.Blood Advances|April 4, 2023
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphomaTycel J Phillips, David Bond, Radihka Takiar, et al.Research Square|February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell LymphomaRichard T Maziarz, Michael R Bishop, Constantine S Tam, et al.Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.Pageof 12